{
    "hands_on_practices": [
        {
            "introduction": "Translating an epigenome editing strategy into a viable therapy requires a clear, quantitative link between the editor's molecular action and the desired physiological outcome. This exercise demonstrates how a fundamental model of gene expression dynamics can be used to predict the degree of therapeutic \"rescue\" achieved by an enhancer-activating editor. By deriving the relationship between enhancer strength and steady-state mRNA levels, you will build a framework for evaluating the potential efficacy of a treatment for haploinsufficiency disorders.",
            "id": "5013104",
            "problem": "A monogenic haploinsufficiency disorder is caused by a pathogenic variant that reduces the activity of a single distal enhancer regulating a therapeutic target gene in human hepatocytes. The enhancer strength is a dimensionless quantity defined as the multiplicative factor by which the enhancer increases the transcription initiation rate relative to basal promoter activity. Assume the following fundamental base:\n- The Central Dogma of Molecular Biology states that gene expression involves transcription of DNA into messenger ribonucleic acid (mRNA) followed by translation, and for a single gene in a homogeneous cell population on the time scale of hours, the mRNA population dynamics are well approximated by a first-order birth–death process.\n- In this regime, the mRNA concentration $m(t)$ obeys $ \\frac{dm}{dt} = k_{\\mathrm{tx}} - k_{\\mathrm{deg}} m$, where $k_{\\mathrm{tx}}$ is the transcription initiation rate and $k_{\\mathrm{deg}}$ is the first-order mRNA degradation rate constant.\n- The transcription initiation rate is proportional to enhancer strength $S$ via $k_{\\mathrm{tx}} = k_{b} S$, where $k_{b}$ is a constant with units of concentration per unit time.\n\nLet $S_{h}$ denote the healthy enhancer strength. In the disease state, the enhancer strength is reduced by a fractional loss $ \\epsilon$ with $0 < \\epsilon < 1$, so that $S_{d} = (1 - \\epsilon) S_{h}$. A translational epigenome editing intervention (for example, a deactivated clustered regularly interspaced short palindromic repeats (CRISPR)-based histone acetyltransferase tether) increases the disease enhancer’s activity by a multiplicative factor $\\alpha$ (with $\\alpha > 1$), such that the post-intervention enhancer strength is $S_{e} = \\alpha S_{d}$.\n\nDefine the steady-state mRNA levels $m_{h}^{*}$, $m_{d}^{*}$, and $m_{e}^{*}$ as the asymptotic solutions of the mRNA dynamics in the healthy, disease, and post-intervention states, respectively. Define the dimensionless rescue fraction\n$$\n\\rho(\\alpha,\\epsilon) = \\frac{ m_{e}^{*} - m_{d}^{*} }{ m_{h}^{*} - m_{d}^{*} }.\n$$\nUsing only the assumptions stated above, derive a closed-form analytic expression for $\\rho(\\alpha,\\epsilon)$ in terms of $\\alpha$ and $\\epsilon$. Express your final answer as a single simplified expression. No numerical evaluation is required, and no units are to be included in the final expression.",
            "solution": "The problem requires the derivation of a closed-form analytic expression for the dimensionless rescue fraction $\\rho(\\alpha,\\epsilon)$. The derivation will begin by determining the steady-state messenger ribonucleic acid (mRNA) concentrations for the healthy, disease, and post-intervention states, based on the provided first-order model of gene expression dynamics.\n\nThe dynamics of the mRNA concentration, $m(t)$, are described by the ordinary differential equation:\n$$\n\\frac{dm}{dt} = k_{\\mathrm{tx}} - k_{\\mathrm{deg}} m\n$$\nwhere $k_{\\mathrm{tx}}$ is the transcription initiation rate and $k_{\\mathrm{deg}}$ is the mRNA degradation rate constant.\n\nAt steady state, the concentration of mRNA is constant, which implies that its time derivative is zero: $\\frac{dm}{dt} = 0$. Let $m^*$ denote the steady-state concentration. Setting the equation to zero yields:\n$$\n0 = k_{\\mathrm{tx}} - k_{\\mathrm{deg}} m^*\n$$\nSolving for $m^*$, we obtain the general expression for the steady-state mRNA concentration:\n$$\nm^* = \\frac{k_{\\mathrm{tx}}}{k_{\\mathrm{deg}}}\n$$\nThe problem states that the transcription rate $k_{\\mathrm{tx}}$ is proportional to the enhancer strength $S$ via the relation $k_{\\mathrm{tx}} = k_{b} S$, where $k_{b}$ is a constant. Substituting this into the expression for $m^*$ gives:\n$$\nm^* = \\frac{k_{b} S}{k_{\\mathrm{deg}}}\n$$\nThis equation establishes a direct proportionality between the steady-state mRNA concentration and the enhancer strength. We can now apply this general result to the three specific states defined in the problem: healthy, disease, and post-intervention.\n\n1.  **Healthy State:**\n    The enhancer strength is $S_{h}$. The corresponding steady-state mRNA concentration, $m_{h}^{*}$, is:\n    $$\n    m_{h}^{*} = \\frac{k_{b} S_{h}}{k_{\\mathrm{deg}}}\n    $$\n\n2.  **Disease State:**\n    The enhancer strength is reduced to $S_{d} = (1 - \\epsilon) S_{h}$, where $\\epsilon$ is the fractional loss satisfying $0 < \\epsilon < 1$. The corresponding steady-state mRNA concentration, $m_{d}^{*}$, is:\n    $$\n    m_{d}^{*} = \\frac{k_{b} S_{d}}{k_{\\mathrm{deg}}} = \\frac{k_{b} (1 - \\epsilon) S_{h}}{k_{\\mathrm{deg}}}\n    $$\n\n3.  **Post-intervention State:**\n    The enhancer strength is increased from the disease state by a multiplicative factor $\\alpha > 1$, resulting in $S_{e} = \\alpha S_{d}$. Substituting the expression for $S_d$, we get $S_{e} = \\alpha (1 - \\epsilon) S_{h}$. The corresponding steady-state mRNA concentration, $m_{e}^{*}$, is:\n    $$\n    m_{e}^{*} = \\frac{k_{b} S_{e}}{k_{\\mathrm{deg}}} = \\frac{k_{b} \\alpha (1 - \\epsilon) S_{h}}{k_{\\mathrm{deg}}}\n    $$\n\nNext, we use these expressions to evaluate the rescue fraction $\\rho(\\alpha,\\epsilon)$, which is defined as:\n$$\n\\rho(\\alpha,\\epsilon) = \\frac{ m_{e}^{*} - m_{d}^{*} }{ m_{h}^{*} - m_{d}^{*} }\n$$\nWe calculate the numerator and the denominator separately.\n\nThe numerator, $m_{e}^{*} - m_{d}^{*}$, represents the gain in steady-state mRNA concentration due to the intervention:\n$$\nm_{e}^{*} - m_{d}^{*} = \\frac{k_{b} \\alpha (1 - \\epsilon) S_{h}}{k_{\\mathrm{deg}}} - \\frac{k_{b} (1 - \\epsilon) S_{h}}{k_{\\mathrm{deg}}}\n$$\nFactoring out the common terms:\n$$\nm_{e}^{*} - m_{d}^{*} = \\left( \\frac{k_{b} S_{h}}{k_{\\mathrm{deg}}} \\right) (\\alpha (1 - \\epsilon) - (1 - \\epsilon)) = \\left( \\frac{k_{b} S_{h}}{k_{\\mathrm{deg}}} \\right) (1 - \\epsilon)(\\alpha - 1)\n$$\n\nThe denominator, $m_{h}^{*} - m_{d}^{*}$, represents the loss in steady-state mRNA concentration due to the disease:\n$$\nm_{h}^{*} - m_{d}^{*} = \\frac{k_{b} S_{h}}{k_{\\mathrm{deg}}} - \\frac{k_{b} (1 - \\epsilon) S_{h}}{k_{\\mathrm{deg}}}\n$$\nFactoring out the common terms:\n$$\nm_{h}^{*} - m_{d}^{*} = \\left( \\frac{k_{b} S_{h}}{k_{\\mathrm{deg}}} \\right) (1 - (1 - \\epsilon)) = \\left( \\frac{k_{b} S_{h}}{k_{\\mathrm{deg}}} \\right) (1 - 1 + \\epsilon) = \\left( \\frac{k_{b} S_{h}}{k_{\\mathrm{deg}}} \\right) \\epsilon\n$$\nThe denominator is non-zero because the problem specifies $0 < \\epsilon < 1$, and the term $\\frac{k_{b} S_{h}}{k_{\\mathrm{deg}}}$ corresponds to the healthy mRNA level, which is physically assumed to be positive.\n\nFinally, we substitute the expressions for the numerator and the denominator back into the definition of $\\rho(\\alpha,\\epsilon)$:\n$$\n\\rho(\\alpha,\\epsilon) = \\frac{\\left( \\frac{k_{b} S_{h}}{k_{\\mathrm{deg}}} \\right) (1 - \\epsilon)(\\alpha - 1)}{\\left( \\frac{k_{b} S_{h}}{k_{\\mathrm{deg}}} \\right) \\epsilon}\n$$\nThe common factor $\\frac{k_{b} S_{h}}{k_{\\mathrm{deg}}}$ cancels from the numerator and the denominator, yielding the simplified expression for the rescue fraction:\n$$\n\\rho(\\alpha,\\epsilon) = \\frac{(1 - \\epsilon)(\\alpha - 1)}{\\epsilon}\n$$\nThis is the required closed-form analytic expression for $\\rho(\\alpha,\\epsilon)$ in terms of only $\\alpha$ and $\\epsilon$.",
            "answer": "$$\n\\boxed{\\frac{(1 - \\epsilon)(\\alpha - 1)}{\\epsilon}}\n$$"
        },
        {
            "introduction": "For complex diseases, attacking a single epigenetic pathway may be insufficient, prompting the use of combination therapies. However, it is crucial to determine if the combined effect is merely additive or truly synergistic, where the whole is greater than the sum of its parts. This practice introduces the Bliss independence model, a foundational concept in pharmacology, to calculate the expected effect of two independent agents and quantify any synergistic deviation from this baseline.",
            "id": "5013157",
            "problem": "A translational medicine team is developing an epigenome editing therapy to reactivate fetal hemoglobin at the $\\text{HBG}$ locus for sickle cell disease. They use two programmable epigenome editors: deactivated Cas9 (dCas9) fused to Ten-Eleven Translocation 1 ($\\text{TET1}$) for locus-specific DNA demethylation (agent $A$), and dCas9 fused to the histone acetyltransferase $\\text{p300}$ for targeted histone acetylation (agent $B$). The outcome is quantified as a normalized fractional effect on $\\text{HBG}$ expression, $E \\in [0,1]$, where $E=0$ denotes baseline (no activation) and $E=1$ denotes the maximal effect under the chosen assay conditions. Single-agent editing yields mean fractional effects $E_A = 0.38$ for agent $A$ and $E_B = 0.47$ for agent $B$. The observed combined treatment produces $E_{AB}^{\\text{obs}} = 0.72$.\n\nStarting from the core definition of statistical independence and the interpretation of $E$ as the probability that a cell is shifted into the activated state by a given agent under assay conditions, derive the expected combined fractional effect $E_{AB}^{\\text{exp}}$ for jointly applying agents $A$ and $B$ when their actions are independent. Then, define the Bliss synergy score $S$ as the deviation $S = E_{AB}^{\\text{obs}} - E_{AB}^{\\text{exp}}$ and compute $S$ using the data above. Round your final numerical answer to four significant figures. Express the final result as a decimal number without a percentage sign.",
            "solution": "This problem requires the calculation of the Bliss synergy score, $S$, which quantifies the deviation of an observed combined effect from the effect expected under the assumption of statistical independence.\n\nFirst, we derive the formula for the expected combined effect, $E_{AB}^{\\text{exp}}$, based on the Bliss independence model. The fractional effect $E$ is interpreted as the probability that an agent successfully activates a cell.\n-   The probability that agent $A$ activates a cell is $P(A) = E_A = 0.38$.\n-   The probability that agent $B$ activates a cell is $P(B) = E_B = 0.47$.\n\nThe probability that an agent *fails* to activate a cell is the complement:\n-   Probability of failure for agent $A$: $P(A^c) = 1 - E_A = 1 - 0.38 = 0.62$.\n-   Probability of failure for agent $B$: $P(B^c) = 1 - E_B = 1 - 0.47 = 0.53$.\n\nIf the two agents act independently, the probability that *both* fail to activate a cell is the product of their individual failure probabilities:\n$$P(A^c \\cap B^c) = P(A^c) \\times P(B^c) = (1 - E_A)(1 - E_B)$$\n\nThe expected combined effect, $E_{AB}^{\\text{exp}}$, is the probability that *at least one* agent succeeds, which is the complement of both agents failing:\n$$E_{AB}^{\\text{exp}} = 1 - P(A^c \\cap B^c) = 1 - (1 - E_A)(1 - E_B)$$\nThis is the mathematical definition of Bliss independence.\n\nNow, we substitute the given values to calculate $E_{AB}^{\\text{exp}}$:\n$$E_{AB}^{\\text{exp}} = 1 - (1 - 0.38)(1 - 0.47)$$\n$$E_{AB}^{\\text{exp}} = 1 - (0.62)(0.53)$$\n$$E_{AB}^{\\text{exp}} = 1 - 0.3286$$\n$$E_{AB}^{\\text{exp}} = 0.6714$$\n\nThe Bliss synergy score $S$ is defined as the difference between the observed combined effect, $E_{AB}^{\\text{obs}}$, and the expected effect under independence:\n$$S = E_{AB}^{\\text{obs}} - E_{AB}^{\\text{exp}}$$\nUsing the given value $E_{AB}^{\\text{obs}} = 0.72$, we calculate $S$:\n$$S = 0.72 - 0.6714$$\n$$S = 0.0486$$\nThe problem requires the final answer to be rounded to four significant figures. The calculated value $0.0486$ has three significant figures. To express it with four, we add a trailing zero.\n$$S = 0.04860$$\nA positive score indicates synergy, meaning the combined effect is greater than the sum of the parts predicted by the independence model.",
            "answer": "$$\n\\boxed{0.04860}\n$$"
        },
        {
            "introduction": "The long-term success of an epigenetic therapy hinges on the stability of the edits it installs. This practice explores the durability of epigenetic memory by modeling the decay of a repressive histone mark using first-order kinetics. You will calculate the \"epigenetic half-life\" of the mark and see how it can be modulated by a small-molecule inhibitor, providing a quantitative measure of therapeutic persistence.",
            "id": "5013122",
            "problem": "A translational epigenomic therapy uses clustered regularly interspaced short palindromic repeats (CRISPR) with catalytically dead CRISPR-associated protein 9 (dCas9) fused to a Krüppel-associated box (KRAB) domain and a histone methyltransferase to deposit the repressive histone mark histone H3 lysine 9 trimethylation (H3K9me3) at a pathogenic enhancer. After the editing complex is withdrawn, maintenance of repression depends on the persistence of the H3K9me3 mark in the face of demethylation. Assume the following scientifically grounded model.\n\n1. Let $p(t)$ denote the fraction of nucleosomes at the targeted locus carrying H3K9me3 at time $t$ after withdrawal of the editor. Empirically, mark loss is well-approximated by first-order kinetics under constant demethylase activity: $\\frac{dp}{dt} = -\\lambda_{\\mathrm{eff}}\\,p(t)$, where $\\lambda_{\\mathrm{eff}}$ is the effective first-order turnover rate constant.\n\n2. A small-molecule competitive inhibitor is co-administered to reduce histone demethylase activity. Under rapid equilibrium binding between the inhibitor and the demethylase, the inhibitor dissociation constant $K_i$ satisfies $K_i = \\frac{[E][I]}{[EI]}$, and the active enzyme fraction is $f_{\\mathrm{active}} = \\frac{[E]}{[E] + [EI]} = \\frac{1}{1 + [I]/K_i}$. The effective turnover rate scales with the active enzyme fraction as $\\lambda_{\\mathrm{eff}} = \\lambda_0\\,f_{\\mathrm{active}}$, where $\\lambda_0$ is the baseline turnover rate without inhibitor.\n\nStarting from these foundations, derive an analytic expression for the epigenetic memory half-life $t_{1/2}$ in terms of $\\lambda_0$, $[I]$, and $K_i$. Then, using $\\lambda_0 = 0.12\\,\\mathrm{day}^{-1}$, $[I] = 200\\,\\mathrm{nM}$, and $K_i = 80\\,\\mathrm{nM}$, compute the numerical value of $t_{1/2}$. Express the final result in days and round your answer to three significant figures.",
            "solution": "The problem asks for an analytic expression for the epigenetic memory half-life, $t_{1/2}$, and its numerical value, based on a model of histone mark decay modulated by a competitive inhibitor.\n\nThe decay of the fraction of nucleosomes with the H3K9me3 mark, $p(t)$, is described by a first-order kinetic process:\n$$\n\\frac{dp}{dt} = -\\lambda_{\\mathrm{eff}}\\,p(t)\n$$\nwhere $\\lambda_{\\mathrm{eff}}$ is the effective first-order turnover rate constant. The solution to this differential equation is an exponential decay function:\n$$\np(t) = p(0) \\exp(-\\lambda_{\\mathrm{eff}}t)\n$$\nwhere $p(0)$ is the initial fraction of marked nucleosomes at time $t=0$.\n\nThe half-life, $t_{1/2}$, is the time required for $p(t)$ to decrease to half of its initial value. Setting $p(t_{1/2}) = \\frac{1}{2}p(0)$:\n$$\n\\frac{1}{2}p(0) = p(0) \\exp(-\\lambda_{\\mathrm{eff}}t_{1/2})\n$$\nSolving for $t_{1/2}$ yields the standard expression for half-life in a first-order process:\n$$\nt_{1/2} = \\frac{\\ln(2)}{\\lambda_{\\mathrm{eff}}}\n$$\nThe problem states that the effective turnover rate, $\\lambda_{\\mathrm{eff}}$, is modulated by a competitive inhibitor:\n$$\n\\lambda_{\\mathrm{eff}} = \\lambda_0 f_{\\mathrm{active}} = \\lambda_0 \\left(\\frac{1}{1 + \\frac{[I]}{K_i}}\\right)\n$$\nwhere $\\lambda_0$ is the baseline rate, $[I]$ is the inhibitor concentration, and $K_i$ is the inhibitor dissociation constant.\n\nSubstituting this expression for $\\lambda_{\\mathrm{eff}}$ into the half-life equation gives the desired analytic expression:\n$$\nt_{1/2} = \\frac{\\ln(2)}{\\lambda_0 \\left(\\frac{1}{1 + [I]/K_i}\\right)}\n$$\n$$\nt_{1/2} = \\frac{\\ln(2)}{\\lambda_0} \\left(1 + \\frac{[I]}{K_i}\\right)\n$$\nThis expression shows that the inhibitor extends the baseline half-life by a factor of $(1 + [I]/K_i)$.\n\nNext, we compute the numerical value of $t_{1/2}$ using the provided data:\n$\\lambda_0 = 0.12\\,\\mathrm{day}^{-1}$, $[I] = 200\\,\\mathrm{nM}$, and $K_i = 80\\,\\mathrm{nM}$.\n\nFirst, calculate the dimensionless ratio of inhibitor concentration to its dissociation constant:\n$$\n\\frac{[I]}{K_i} = \\frac{200\\,\\mathrm{nM}}{80\\,\\mathrm{nM}} = 2.5\n$$\nNow, substitute this value and the other parameters into the derived expression for $t_{1/2}$:\n$$\nt_{1/2} = \\frac{\\ln(2)}{0.12\\,\\mathrm{day}^{-1}} (1 + 2.5)\n$$\n$$\nt_{1/2} = \\frac{\\ln(2)}{0.12} (3.5)\\,\\mathrm{days}\n$$\nUsing the value $\\ln(2) \\approx 0.693147$:\n$$\nt_{1/2} \\approx \\frac{0.693147}{0.12} \\times 3.5\\,\\mathrm{days}\n$$\n$$\nt_{1/2} \\approx 5.7762 \\times 3.5\\,\\mathrm{days}\n$$\n$$\nt_{1/2} \\approx 20.2167\\,\\mathrm{days}\n$$\nThe problem requires rounding the final answer to three significant figures.\n$$\nt_{1/2} \\approx 20.2\\,\\mathrm{days}\n$$",
            "answer": "$$\\boxed{20.2}$$"
        }
    ]
}